Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Fong Tse-Ling M.D.; Morgan, Timothy R. M.D.; Phan, Charles G. M.D.; Hoefs, John C. M.D.
Journal of Clinical Gastroenterology: January 1995
Clinical Studies: PDF Only

We report results of dose escalation to 5 or 6 million units (MU) three times weekly (t.i.w.) of interferon-a in 17 consecutive patients with chronic active hepatitis C who were not responding to 3 MU t.i.w. after>12 weeks of therapy. The mean pretreatment alanine aminotransferase (ALT) level was 206 ± 62 U/L and, at the time of dose escalation, 113 ± 71 U/L. Two patients could not tolerate the dose escalation. The remaining 15 patients were treated for an additional 10 ± 3.5 weeks. Three patients had a complete response 3-8 weeks after dose escalation. At the end of high-dose therapy, the mean ALT level was 105 ± 76 U/L (n=15). During the 6-month posttreatment follow-up time, the mean ALT level was 147 ± 85 U/L. All three responders had a relapse. Increasing the dose of interferon-a to 5-6 MU t.i.w. in chronic hepatitis C patients who are not responding to interferon-a, 3 MU t.i.w., at the 12th week of therapy is unlikely to result in sustained normalization of ALT levels.

© Lippincott-Raven Publishers.